AI-as-a-Service tools to be the epicentre of the Biosimilar Insulin...

added blog Health

2022-10-18 20:40:07 - Translate -

AI-as-a-Service tools to be the epicentre of the Biosimilar Insulin Market, reaching US$ 5.9 Bn

The biosimilar insulin market reached US$ 1.3 Bn at the end of 2021 and is expected to surge ahead at a CAGR of 14.9% over the forecast period (2022-2032). As biologics manufacturing in emerging countries has increased, the global pharmaceutical industry has become even more competitive. Companies in these fields will need to constantly upgrade their specialized...

0 Comments 0 Shares 2K Views 0 Reviews